
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.
MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 10, 8, 2, 63, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 25 molecules, respectively.
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.
MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 10, 8, 2, 63, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 25 molecules, respectively.
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
314 Pages
- Introduction
- Global Markets Direct Report Coverage
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Overview
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Companies Involved in Therapeutics Development
- AbbVie Inc
- Acticule Life Sciences Ltd
- Acurx Pharmaceuticals Inc
- AEON Medix Inc
- AimMax Therapeutics Inc
- AlphaMab Co Ltd
- Amicrobe Inc
- Amprologix Ltd
- AnyGen Co Ltd
- Aphios Corp
- Aridis Pharmaceuticals Inc
- Arietis Corp
- Aurigene Discovery Technologies Ltd
- Basilea Pharmaceutica Ltd
- Bharat Biotech Ltd
- Biomendics LLC
- BioPlx Microbiomics Pvt Ltd
- Bioseka UAB
- Bioversys AG
- Botanix Pharmaceuticals Ltd
- Cantab Anti-infectives Ltd
- Cellics Therapeutics Inc
- Centivax Inc
- Chengdu Olymvax Biopharmaceuticals Inc
- Crestone Inc
- CrystalGenomics Inc
- CSA Biotechnologies LLC
- Curza Global LLC
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- DeNovaMed Inc
- Destiny Pharma Plc
- Eagle Pharmaceuticals Inc
- Enesi Pharma Ltd
- ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
- Exbaq LLC
- Global BioLife Inc Ltd
- Helperby Therapeutics Group Ltd
- Histogen Inc
- Hsiri Therapeutics LLC
- HyPharm GmbH
- ImmunArtes LLC
- Immupharma Plc
- Inimmune Corp
- Integrated BioTherapeutics Inc
- ioGenetics Inc
- Johnson & Johnson
- KBP Biosciences Co Ltd
- Lakewood-Amedex Inc
- Lead Discovery Center GmbH
- LegoChem Biosciences Inc
- Lysimmune BioScience
- Lyticon LLC
- Madam Therapeutics BV
- Matrisys Bioscience Inc
- Meiji Seika Pharma Co Ltd
- MGB Biopharma Ltd
- Microbiotix Inc
- MicuRx Pharmaceuticals Inc
- Naicons Srl
- Neupharma Srl
- Novabiotics Ltd
- Novalex Therapeutics Inc
- NovoBiotic Pharmaceuticals LLC
- Olgram SAS
- Opal Biosciences Ltd
- Oppilotech Ltd
- Oragenics Inc
- Oryn Therapeutics
- Oxford Drug Design Ltd
- Peptineo
- Pharma Holdings AS
- Phico Therapeutics Ltd
- Prokaryotics Inc
- Prommune Inc
- Q2 Pharma Ltd
- QureTech Bio AB
- Recce Pharmaceuticals Ltd
- Sano Chemicals Inc
- Scandion Oncology AS
- SciBac Inc
- Sentinella Pharmaceuticals Inc
- Shanghai Shangyao Xinya Pharmaceutical Co Ltd
- Shanghai Space Peptides Pharmaceutical Co Ltd
- Sinsa Labs Inc
- Skye Bioscience Inc
- Sorrento Therapeutics Inc
- Synspira Therapeutics Inc
- TaeJoon Pharmaceuticals Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- TAXIS Pharmaceuticals Inc
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Theravance Biopharma Inc
- Trellis Bioscience Inc
- Venomyx Inc
- Viosera Therapeutics
- Vitas Pharma Research Pvt Ltd
- VLP Biotech Inc
- Wockhardt Ltd
- Yungjin Pharm Co Ltd
- Zhuhai Trinomab Biotechnology Co Ltd
- Zydus Lifesciences Ltd
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profiles
- (meropenem + piperacillin + tazobactam) – Drug Profile
- (mupirocin calcium + neomycin sulfate + HT-61) – Drug Profile
- ACH-702 – Drug Profile
- ACX-375C – Drug Profile
- ADEP-4 – Drug Profile
- afabicin – Drug Profile
- AGM-290 – Drug Profile
- ALS-2 – Drug Profile
- ALS-3 – Drug Profile
- ALS-4 – Drug Profile
- AM-0016 – Drug Profile
- Anti-bacterial 1 – Drug Profile
- APY-281 – Drug Profile
- AU-1702014 – Drug Profile
- B-2088 – Drug Profile
- BDM-I – Drug Profile
- berkeleylactone A – Drug Profile
- Beta Lactam Antibiotics + BPEI – Drug Profile
- BioPlx-01KS – Drug Profile
- BioPlx-01WT – Drug Profile
- BSK-003 – Drug Profile
- BTX-1801 – Drug Profile
- BV-200 – Drug Profile
- CAL-02 – Drug Profile
- cefilavancin – Drug Profile
- ceftobiprole medocaril – Drug Profile
- Cellular Immunotherapy for MRSA Infections – Drug Profile
- CG-549 – Drug Profile
- ClyO – Drug Profile
- contezolid – Drug Profile
- contezolid acefosamil – Drug Profile
- CRS-0540 – Drug Profile
- CSA-13 – Drug Profile
- CTI-005 – Drug Profile
- CTI-036 – Drug Profile
- CYTOLYSIN – Drug Profile
- CZ-25 – Drug Profile
- CZ-52 – Drug Profile
- dalbavancin – Drug Profile
- darwinolide – Drug Profile
- delpazolid – Drug Profile
- diflunisal – Drug Profile
- Drugs for Methicillin-Resistant Staphylococcus Aureus Infections – Drug Profile
- emricasan – Drug Profile
- EP-67 – Drug Profile
- Epidermicin NI-01 – Drug Profile
- EVQ-221 – Drug Profile
- exeporfinium chloride – Drug Profile
- F-12 – Drug Profile
- F-19 – Drug Profile
- firmocidin – Drug Profile
- GmPcide-1 – Drug Profile
- HT-01 – Drug Profile
- HT-02 – Drug Profile
- Humimycin A – Drug Profile
- HY-004B8b – Drug Profile
- HY-005B8a – Drug Profile
- HY-133 – Drug Profile
- IBN-1 – Drug Profile
- infectious disease vaccine – Drug Profile
- IOG-101 – Drug Profile
- IPP-203101 – Drug Profile
- KBP-7072 – Drug Profile
- KKL-35 – Drug Profile
- KN-043 – Drug Profile
- KVH-147 – Drug Profile
- LB-2 – Drug Profile
- LCB-010699 – Drug Profile
- levonadifloxacin – Drug Profile
- LI-03 – Drug Profile
- LTX-109 – Drug Profile
- lysostaphin – Drug Profile
- Marinus – Drug Profile
- MGBBP-3 – Drug Profile
- Monoclonal Antibodies for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profile
- Mul-1867 – Drug Profile
- MUT-001 – Drug Profile
- NAI-107 – Drug Profile
- NAI-603 – Drug Profile
- NAIAPOL-2001 – Drug Profile
- NB-3111 – Drug Profile
- Novo-29 – Drug Profile
- NP-108 – Drug Profile
- NP-432 – Drug Profile
- Nu-3 – Drug Profile
- NVB-333 – Drug Profile
- OG-253 – Drug Profile
- OTP-602 – Drug Profile
- P-100031 – Drug Profile
- Panaecin – Drug Profile
- PIND-146007 – Drug Profile
- PK-150 – Drug Profile
- Protein for Infectious Disease and Inflammation – Drug Profile
- Qn-2705 – Drug Profile
- RECCE-327 – Drug Profile
- Recombinant Protein for Infectious Diseases – Drug Profile
- Recombinant Protein for MRSA Infections – Drug Profile
- Recombinant Proteins for Anthrax and Methicillin Resistant Staphylococcus Aureus (MRSA) Infections – Drug Profile
- SAAP-148 – Drug Profile
- SASPjectPT-1.2 – Drug Profile
- SC-5005 – Drug Profile
- SCA-50 – Drug Profile
- SCB-203 – Drug Profile
- SK-0392 – Drug Profile
- SM-1S26 – Drug Profile
- Small Molecule for Gram-Positive Bacterial Infections – Drug Profile
- Small Molecule for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profile
- Small Molecule for Methicillin-Resistant Staphylococcus aureus Infections – Drug Profile
- Small Molecule to Inhibit crtN for Staphylococcus aureus Infections – Drug Profile
- Small Molecule to Inhibit DNA Gyrase for Gram Positive Bacterial Infections – Drug Profile
- Small Molecule to Inhibit FabI for MRSA Infection – Drug Profile
- Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections – Drug Profile
- Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections – Drug Profile
- Small Molecule to Inhibit Wall Teichoic Acid for MRSA Infections – Drug Profile
- Small Molecules for Bacterial Infections – Drug Profile
- Small Molecules for Bacterial Infections and Bone Disorders – Drug Profile
- Small Molecules for Gram Positive Bacterial Infections – Drug Profile
- Small Molecules for Gram-Positive Bacterial Infections – Drug Profile
- Small Molecules for Gram-Positive Bacterial Infections and MRSA Infections – Drug Profile
- Small Molecules for Infectious Diseases – Drug Profile
- Small Molecules for Methicillin Resistant Staphylococcus aureus Infections – Drug Profile
- Small Molecules for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profile
- Small Molecules for MRSA and VRSA Infections – Drug Profile
- Small Molecules for MRSA Infections – Drug Profile
- Small Molecules for Staphylococcal Infections – Drug Profile
- Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections – Drug Profile
- Small Molecules to Inhibit Acyl Carrier Protein Synthase for Methicillin-Resistant Staphylococcus aureus Infections – Drug Profile
- Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections – Drug Profile
- Small Molecules to Inhibit Bacterial Cell Membrane for MRSA Infection – Drug Profile
- Small Molecules to Inhibit bNOS for MRSA Infections – Drug Profile
- Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections – Drug Profile
- Small Molecules to Inhibit Fabl for Staphylococcal Aureus and MRSA Infections – Drug Profile
- Small Molecules to Inhibit ftsz for Infectious Disease – Drug Profile
- Small Molecules to Inhibit KasA for Gram-Positive and Gram-Negative Bacterial Infections – Drug Profile
- Small Molecules to Inhibit Lipid II for Methicillin-Resistant Staphylococcus aureus Associated Skin Infections – Drug Profile
- Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections – Drug Profile
- Small Molecules to Inhibit MenA for Bacterial Infections – Drug Profile
- Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections – Drug Profile
- Small Molecules to Inhibit MRAY for Methicillin-Resistant Staphylococcus aureus Infections – Drug Profile
- Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections – Drug Profile
- Small Molecules to Inhibit Pyruvate Kinase for MRSA Infections – Drug Profile
- Small Molecules to Inhibit Sortase A for Gram-Positive Bacterial Infections – Drug Profile
- SNSP-113 – Drug Profile
- SOM-001 – Drug Profile
- Staphylococcus aureus (bivalent, virus like particle) vaccine – Drug Profile
- Staphylococcus aureus (multivalent) vaccine – Drug Profile
- Staphylococcus aureus vaccine – Drug Profile
- STI-001 – Drug Profile
- Synthetic Peptide to Disrupt Bacterial Cell Membrane for Bacterial Infections – Drug Profile
- Synthetic Peptides for Gram Positive Bacterial Infections – Drug Profile
- Synthetic Peptides for MRSA Infections – Drug Profile
- Synthetic Peptides for Staphylococcus Aureus Infections and H1N1 Influenza – Drug Profile
- Synthetic Peptides to Disrupt Bacterial Cell Membrane for MRSA and Escherichia coli Infections – Drug Profile
- T-145 – Drug Profile
- targocil – Drug Profile
- Taro Inhibitor – Drug Profile
- taromycin A – Drug Profile
- teicoplanin – Drug Profile
- Teixobactin – Drug Profile
- TNM-012 – Drug Profile
- TNS-18 – Drug Profile
- Tolasure – Drug Profile
- TP-0480066 – Drug Profile
- TPH-101 – Drug Profile
- TRL-1068 – Drug Profile
- TS-2037 – Drug Profile
- TXA-709 – Drug Profile
- Vaccine for MRSA Infections – Drug Profile
- VT-02 – Drug Profile
- WCK-4086 – Drug Profile
- WLBU-2 – Drug Profile
- YSA-2021 – Drug Profile
- YV-11455 – Drug Profile
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Product Development Milestones
- Featured News & Press Releases
- Jul 19, 2022: Destiny Pharma announces positive update from US FDA on XF-73 phase 3
- Jul 08, 2022: Prokaryotics receives SBIR phase IIB award supporting preclinical candidate selection for ß-lactam potentiator program
- May 26, 2022: Rationale for FDA’s position on oxacillin breakpoints for staphylococcus
- Mar 31, 2022: Data on the antimicrobial activity of XF-73 against bacteria within biofilms to be presented at prestigious 2022 ECCMID Congress
- Feb 08, 2022: Positive feedback from EMA on XF-73 Nasal gel phase 3 programme
- Oct 12, 2021: Prokaryotics announces that two patents covering novel compounds which restore the efficacy of commonly used ß-lactams against MRSA have been issued by the U.S. Patent and Trademark Office
- May 04, 2021: Botanix update on BTX 1801 clinical development
- Mar 31, 2021: Aptorum Group announces dosing first human subject in a phase I clinical trial of ALS-4, a first-in-class small molecule drug designed to treat infections caused by Staphylococcus aureus including Methicillin-Resistant Staphylococcus aureus
- Mar 29, 2021: Destiny Pharma reports positive phase 2b results for XF-73 Nasal Gel
- Mar 18, 2021: Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis
- Feb 19, 2021: Botanix attends 2nd Dermatology Drug Development Summit Europe
- Jan 20, 2021: Aptorum Group receives clearance from health canada to initiate a phase 1 clinical trial for ALS-4, a small molecule drug for infections caused by staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
- Dec 21, 2020: Aptorum Group announces submission of clinical trial application for ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
- Sep 02, 2020: Dartmouth-led team engineers new treatment for drug-resistant bacterial infections
- Sep 01, 2020: Aptorum Group announces further positive data on ALS-4 against MRSA wound infection and MRSA Bacteraemia against Linezolid and Vancomycin respectively in in vivo models
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Universities/Institutes, 2022
- Table 9: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 10: Number of Products under Development by Universities/Institutes, 2022 (Contd..2)
- Table 11: Products under Development by Companies, 2022
- Table 12: Products under Development by Companies, 2022 (Contd..1)
- Table 13: Products under Development by Companies, 2022 (Contd..2)
- Table 14: Products under Development by Companies, 2022 (Contd..3)
- Table 15: Products under Development by Companies, 2022 (Contd..4)
- Table 16: Products under Development by Companies, 2022 (Contd..5)
- Table 17: Products under Development by Companies, 2022 (Contd..6)
- Table 18: Products under Development by Universities/Institutes, 2022
- Table 19: Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 20: Products under Development by Universities/Institutes, 2022 (Contd..2)
- Table 21: Number of Products by Stage and Target, 2022
- Table 22: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 23: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 24: Number of Products by Stage and Mechanism of Action, 2022
- Table 25: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 26: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 27: Number of Products by Stage and Route of Administration, 2022
- Table 28: Number of Products by Stage and Molecule Type, 2022
- Table 29: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AbbVie Inc, 2022
- Table 30: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Acticule Life Sciences Ltd, 2022
- Table 31: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Acurx Pharmaceuticals Inc, 2022
- Table 32: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AEON Medix Inc, 2022
- Table 33: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AimMax Therapeutics Inc, 2022
- Table 34: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AlphaMab Co Ltd, 2022
- Table 35: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Amicrobe Inc, 2022
- Table 36: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Amprologix Ltd, 2022
- Table 37: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AnyGen Co Ltd, 2022
- Table 38: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aphios Corp, 2022
- Table 39: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aridis Pharmaceuticals Inc, 2022
- Table 40: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Arietis Corp, 2022
- Table 41: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aurigene Discovery Technologies Ltd, 2022
- Table 42: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Basilea Pharmaceutica Ltd, 2022
- Table 43: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bharat Biotech Ltd, 2022
- Table 44: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Biomendics LLC, 2022
- Table 45: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by BioPlx Microbiomics Pvt Ltd, 2022
- Table 46: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bioseka UAB, 2022
- Table 47: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bioversys AG, 2022
- Table 48: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Botanix Pharmaceuticals Ltd, 2022
- Table 49: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cantab Anti-infectives Ltd, 2022
- Table 50: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cellics Therapeutics Inc, 2022
- Table 51: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Centivax Inc, 2022
- Table 52: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022
- Table 53: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Crestone Inc, 2022
- Table 54: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CrystalGenomics Inc, 2022
- Table 55: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CSA Biotechnologies LLC, 2022
- Table 56: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Curza Global LLC, 2022
- Table 57: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Daiichi Sankyo Co Ltd, 2022
- Table 58: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Debiopharm International SA, 2022
- Table 59: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by DeNovaMed Inc, 2022
- Table 60: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Destiny Pharma Plc, 2022
- Table 61: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Eagle Pharmaceuticals Inc, 2022
- Table 62: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Enesi Pharma Ltd, 2022
- Table 63: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ESA Patentverwertungsagentur Sachsen-Anhalt GmbH, 2022
- Table 64: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Exbaq LLC, 2022
- Table 65: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Global BioLife Inc Ltd, 2022
- Table 66: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Helperby Therapeutics Group Ltd, 2022
- Table 67: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Histogen Inc, 2022
- Table 68: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Hsiri Therapeutics LLC, 2022
- Table 69: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by HyPharm GmbH, 2022
- Table 70: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ImmunArtes LLC, 2022
- Table 71: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Immupharma Plc, 2022
- Table 72: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Inimmune Corp, 2022
- Table 73: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Integrated BioTherapeutics Inc, 2022
- Table 74: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ioGenetics Inc, 2022
- Table 75: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Johnson & Johnson, 2022
- Table 76: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by KBP Biosciences Co Ltd, 2022
- Table 77: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lakewood-Amedex Inc, 2022
- Table 78: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lead Discovery Center GmbH, 2022
- Table 79: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by LegoChem Biosciences Inc, 2022
- Table 80: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lysimmune BioScience, 2022
- Table 81: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lyticon LLC, 2022
- Table 82: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Madam Therapeutics BV, 2022
- Table 83: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Matrisys Bioscience Inc, 2022
- Table 84: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Meiji Seika Pharma Co Ltd, 2022
- Table 85: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MGB Biopharma Ltd, 2022
- Table 86: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Microbiotix Inc, 2022
- Table 87: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MicuRx Pharmaceuticals Inc, 2022
- Table 88: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Naicons Srl, 2022
- Table 89: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Neupharma Srl, 2022
- Table 90: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novabiotics Ltd, 2022
- Table 91: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novalex Therapeutics Inc, 2022
- Table 92: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovoBiotic Pharmaceuticals LLC, 2022
- Table 93: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Olgram SAS, 2022
- Table 94: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Opal Biosciences Ltd, 2022
- Table 95: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oppilotech Ltd, 2022
- Table 96: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oragenics Inc, 2022
- Table 97: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oryn Therapeutics, 2022
- Table 98: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oxford Drug Design Ltd, 2022
- Table 99: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Peptineo, 2022
- Table 100: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Pharma Holdings AS, 2022
- Table 101: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Phico Therapeutics Ltd, 2022
- Table 102: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Prokaryotics Inc, 2022
- Table 103: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Prommune Inc, 2022
- Table 104: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Q2 Pharma Ltd, 2022
- Table 105: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by QureTech Bio AB, 2022
- Table 106: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Recce Pharmaceuticals Ltd, 2022
- Table 107: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sano Chemicals Inc, 2022
- Table 108: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Scandion Oncology AS, 2022
- Table 109: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by SciBac Inc, 2022
- Table 110: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sentinella Pharmaceuticals Inc, 2022
- Table 111: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Shanghai Shangyao Xinya Pharmaceutical Co Ltd, 2022
- Table 112: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, 2022
- Table 113: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sinsa Labs Inc, 2022
- Table 114: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Skye Bioscience Inc, 2022
- Table 115: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sorrento Therapeutics Inc, 2022
- Table 116: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Synspira Therapeutics Inc, 2022
- Table 117: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
- Table 118: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
- Table 119: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TAXIS Pharmaceuticals Inc, 2022
- Table 120: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TGV-Inhalonix Inc, 2022
- Table 121: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
- Table 122: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Theravance Biopharma Inc, 2022
- Table 123: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Trellis Bioscience Inc, 2022
- Table 124: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Venomyx Inc, 2022
- Table 125: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Viosera Therapeutics, 2022
- Table 126: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Vitas Pharma Research Pvt Ltd, 2022
- Table 127: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by VLP Biotech Inc, 2022
- Table 128: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Wockhardt Ltd, 2022
- Table 129: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Yungjin Pharm Co Ltd, 2022
- Table 130: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
- Table 131: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Zydus Lifesciences Ltd, 2022
- Table 132: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022
- Table 133: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..1)
- Table 134: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..2)
- Table 135: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..3)
- Table 136: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..4)
- Table 137: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..5)
- Table 138: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..6)
- Table 139: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..7)
- Table 140: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..8)
- Table 141: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..9)
- Table 142: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.